Jef Akst
Managing Editor at BioSpace
Managing Editor at @BioSpace | [email protected]
Articles
-
3 days ago |
biospace.com | Heather McKenzie |Jef Akst |Annalee Armstrong
> Listen on Spotify> Listen on Apple Products> Listen on Amazon Music> Listen on iHeartThe words of the week so far in biopharma are “deals” and “cancer”—or, more specifically, money being invested in cancer and other key therapeutic areas. With the American Society of Clinical Oncology’s annual conference underway in Chicago, Bristol Myers Squibb got in the PD-1/PD-L1xVEGF game, paying potentially more than $11 billion to co-develop BioNTech’s solid tumor bispecific BNT327.
-
1 week ago |
biospace.com | Heather McKenzie |Jef Akst |Annalee Armstrong
> Listen on Spotify> Listen on Apple Products> Listen on Amazon Music> Listen on iHeartThe name of the biopharma game this season is vaccines—and RFK Jr. wasted no time returning from Memorial Day Weekend before making news on this front, removing the COVID-19 vaccine from the list of recommended immunizations for healthy kids and pregnant women on Tuesday.
-
2 weeks ago |
biospace.com | Heather McKenzie |Jef Akst |Annalee Armstrong |Dan Samorodnitsky
> Listen on Spotify> Listen on Apple Products> Listen on Amazon Music> Listen on iHeartPfizer stole the headlines this week with a pact worth up to $6 billion with Chinese biotech 3SBio for a PD-1/VEGF candidate just three months after inking a clinical trials collab for a similar drug with Summit Therapeutics. It’s the largest Chinese licensing deal in recent memory, as pharmas continue to turn to the country to fill their pipelines.
-
3 weeks ago |
biospace.com | Heather McKenzie |Jef Akst |Annalee Armstrong |Dan Samorodnitsky
> Listen on Spotify> Listen on Apple Products> Listen on Amazon Music> Listen on iHeartPresident Donald Trump unveiled a sweeping drug pricing policy this week, seeking to lower drug prices in the U.S. by up to 80% through a reprisal of the Most Favored Nation rule he attempted to introduce in his first term. The rule would essentially link U.S. prices to those paid in other nations where medications are cheaper.
-
1 month ago |
biospace.com | Heather McKenzie |Jef Akst |Annalee Armstrong |Dan Samorodnitsky
> Listen on Spotify> Listen on Apple Products> Listen on Amazon Music> Listen on iHeartIn his effort to onshore manufacturing, President Donald Trump issued an executive order on Monday afternoon ordering the FDA to ease permitting processes for new and expanded U.S. facilities. The announcement comes as more and more Big Pharma companies commit billions to expanding their U.S. footprints.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 997
- Tweets
- 340
- DMs Open
- No
I'm looking for an editor to join our team here @biospace. If you are a journalist with an interest in the business of biopharma, let me know! https://t.co/HahZTQSVKf
FDA's Peter Marks once again from #ASGCT2024, this time on global regulatory convergence, saying that for rare diseases in particular, lack of regulatory standardization presents big challenges. @Slabodkin reporting for @BioSpace https://t.co/LCRy428ZPK #ASGCT #ASGCT24
“$4.25 million!!!” That’s the email FDA’s Peter Marks said he received from Commissioner Robert Califf when Orchard revealed the price tag of its newly approved gene therapy Lenmeldy. Check out my @biospace recap of the #ASGCT2024 fireside chat: https://t.co/PlR8mCDuxS
